GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Debt-to-EBITDA

Walvax Biotechnology Co (SZSE:300142) Debt-to-EBITDA : 3.32 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Walvax Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥356 Mil. Walvax Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥448 Mil. Walvax Biotechnology Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥243 Mil. Walvax Biotechnology Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 3.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Walvax Biotechnology Co's Debt-to-EBITDA or its related term are showing as below:

SZSE:300142' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.97   Med: 0.35   Max: 4.76
Current: 1.77

During the past 13 years, the highest Debt-to-EBITDA Ratio of Walvax Biotechnology Co was 4.76. The lowest was -2.97. And the median was 0.35.

SZSE:300142's Debt-to-EBITDA is ranked worse than
51.52% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.675 vs SZSE:300142: 1.77

Walvax Biotechnology Co Debt-to-EBITDA Historical Data

The historical data trend for Walvax Biotechnology Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Debt-to-EBITDA Chart

Walvax Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.37 0.35 0.87

Walvax Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.33 0.94 -1.17 3.32

Competitive Comparison of Walvax Biotechnology Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's Debt-to-EBITDA falls into.



Walvax Biotechnology Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Walvax Biotechnology Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(350.933 + 455.491) / 922.157
=0.87

Walvax Biotechnology Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(356.426 + 448.255) / 242.54
=3.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Walvax Biotechnology Co  (SZSE:300142) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Walvax Biotechnology Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co (SZSE:300142) Business Description

Traded in Other Exchanges
N/A
Address
Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Executives
Wu Yun Yan Executives
Zhao Jin Long Executives
Yao Wei Executives
Zhou Hua Executives
Shi Jing Executives
Jiang Run Sheng Directors, executives
Gong Sun Qing Executives
Executives
Yuan Lin Executives
Fang Guo Liang Executives
Li Yun Chun Director
Huang Zhen Director
Zhang Li Secretary Dong
Yang Hong Wei Supervisors
Xu Ke Ren Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines